- Current report filing (8-K)
June 21 2010 - 6:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported):
June 17,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
|
001-32715
|
|
94-3123681
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
135
Beaver Street Waltham, MA
|
|
02452
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item 5.07 Submission of
Matters to a Vote of Security Holders.
Interleukin
Genetics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the
“Annual Meeting”) on June 17, 2010. Holders of 30,010,763 shares of
the Company’s common stock and 5,000,000 shares of the Company’s Series A
preferred stock (the “Preferred Stock”) were present in person or by
proxy. Each share of the Preferred Stock is convertible into
approximately 5.63 shares of the Company’s common stock and is entitled to one
vote for each share of common stock into which it is
convertible. Accordingly, shares representing 89.9 % of the aggregate
voting power were present in person or by proxy at the Annual
Meeting. The following are the results of the two proposals voted on
at the Annual Meeting:
Proposal
1
: William C. Mills III was elected to serve as a Class I
director for a three-year term expiring at the Company’s 2013 annual meeting of
stockholders. The following chart shows the number of votes cast for
the election of Mr. Mills, as well as the number of votes withheld:
|
|
For
|
Withheld
|
|
Common
Stock
|
12,777,774
|
212,149
|
|
Preferred
Stock
|
5,000,000
|
0
|
In
addition, there were 17,020,840 broker non-votes on Proposal 1.
Proposal
2
: The appointment of Grant Thornton LLP as the Company’s
independent public accountant for the fiscal year ending December 31, 2010
was ratified by the stockholders. The following chart shows the
number of votes cast for and against this proposal, as well as the number of
votes that abstained:
|
|
For
|
Against
|
Abstain
|
|
Common
Stock
|
29,919,542
|
63,488
|
27,733
|
|
Preferred
Stock
|
5,000,000
|
0
|
0
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
Interleukin
Genetics, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date:
June 21, 2010
|
|
/s/
ELIOT M. LURIER
|
|
|
|
Eliot
M. Lurier
|
|
|
|
Chief
Financial Officer
|
|
|
|
(Signature)
|
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Dec 2023 to Dec 2024
